Merck KGaA Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Merck KGaA Insights data

Headline Published Journalists
Showing 3 of 60+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 22 Jul 2022 Lorem
Neglected Tropical Diseases: Non-Profits Lead the Way as Private Sectors Lags 30 Jun 2022 Adam Zamecnik
LoA Update: Merck KGaA’s Berzosertib Advancement Prospects Dip in Small-Cell Lung Cancer, Solid Tumors After Phase II Discontinuation 10 Jun 2022 Urte Fultinaviciute
LoA Update: Merck’s schistosomiasis asset levo-praziquantel sees its Likelihood of Approval rise after positive Phase III results 26 Nov 2021 Adam Zamecnik
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer